BioSpace News Archive

BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial.

Amgen announced the presentation of new respiratory data at the American Thoracic Society 2024 International Conference taking place May 12-22 in San Diego.

Calidi Biotherapeutics Inc. announced the acceptance of three abstracts that will be presented in a poster session at the 2024 American Society of Clinical Oncology Annual Meeting, taking place from May 31-June 4, 2024, in Chicago, Illinois.

Merck, known as MSD outside of the United States and Canada, announced that the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA®, Merck’s anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival for the first-line treatment of patients with human epidermal growth factor receptor 2 -positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Minerva Neurosciences, Inc. today reported business updates and financial results for the first quarter of 2024 ending March 31, 2024.

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter (Q1) of 2024, covering the three-month period ended March 31, 2024.

Opthea Limited today announced that two scientific presentations on the sozinibercept (OPT-302) Phase 2 clinical trial results and ongoing Phase 3 clinical trial program will be made at the Retina World Congress (RWC), being held from May 9-12, 2024 in Fort Lauderdale, Florida.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immunology-based therapies for cancer, received notice from NASDAQ on April 30, 2024, that the Company has regained compliance with the $1.00 minimum bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2).

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week ® 2024.

MDxHealth SA announced its financial results for the first quarter ended March 31, 2024 and the closing of a new debt facility with OrbiMed.